Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Solid buying for the day…nice.
Ah. That is where the risk factor comes into play. We are hoping that Buccy is the undiscovered wonder drug. If everyone knew about it, and it was used in 50 countries, we could not have the opportunity to make serious money off this stock. If it was so easy, we would have a triple crown winner every year.
ps. I realize we are not making money off this stock at the moment.
pps. Good luck to all even a pissed off and frustrated Snoopy.
ppps. Come on Doug Flutie. We need that Hail Mary more than ever.
There is also a somewhat new face book chat in the F-book group many are positive there, a few good people there also : ) lately not much talk in any of the groups lol because of course just waiting on the data as u know.
ps. holding of course but ignoring the Negative u know whats lol.....
I think Bucillamine could help with something like but we will see.
📌Post-COVID-19 symptoms can linger for 2 years and are associated with prolonged inflammation.
— Outbreak Updates (@outbreakupdates) May 23, 2023
Patients with prolonged inflammation showed elevated terminally differentiated memory T cells in their blood; 54% had symptoms at 12 months. https://t.co/v02bnYT5xf
China’s New Covid Wave Set to See 65 Million Cases a Week ⚠️ https://t.co/4PVEi0SPI1
— Jess (@MeetJess) May 22, 2023
Gaps always fill…..I’m hoping however that we continue upward. May 12 we had a gap down…it’s filling in.
I am not a scientist and neither is Rubber. We believe in the science behind Bucillamine and that it can be used as an antiinflammatory to combat long covid, restore glutathione levels, work 16X as strong as NAC and reduce symptoms such as fever and chills as proven by PCR numbers. I think this will be clear within a few days. It also will be effective in the USA against Rheumatoid Arthritis and several other conditions. Look it up. There are several other conditions that BUCY works for overseas.
ps. Sheesh
pps. Nobody is happy with the PPS, and it's still a longshot, but many of us will hold for a buyout or wait for the mushrooms industry to explode. Several of us averaged down so all we can do is wait and have hope.
Anyone with any sense and a little powder would be taking a step back, calm down, look at that gap and buy while others are bitching like a bunch of woke schoolgirls.
5/12/2023
Must be a leak, news pending, $$$$$$
Because Buc works.
OK, so why is it up over 25% today with heavy volume?
Price
$0.0566
Day's Change
0.0114 (25.22%)
Bid
0.05
Ask
0.0567
B/A Size
610800x10000
Day's High
0.0566
Day's Low
0.0409
Volume(Heavy Day)
422,541
May 22, 2023 2:55pm ET
What are you waiting for? It's over. Stick a fork in it.
Why continue to hope and pray?
The only people waiting are a few pumpers and bagholders. I'm not waiting for anything, and by the looks of this and other message boards the vast majority are done waiting too. What criteria do you need to see before you admit defeat? Come on and tell us what would make you admit defeat. Is there anything? Christians have been waiting over 2000 years. Is that you with bucillamine?
Gov
I not angry at anyone. And I have lost nothing. You have no idea what you are talking about. Stop your bs. Just wait like everyone else.
would have been nice to have them meet a year ago - I don't think the data hasn't changed or patients been enrolled over the past year.
Yes it matters and yes Bucillamine should do well in restoring it.
Hey There Medicinecat,
The FDA or any DSMB isn’t in the business of being impressed by anything. Our sample is just too small to reach statistical significance with the original endpoints of hospitalizations and death even if we would have gotten to 1000 the last 290 or so what have been during the Omicron variant which wouldn’t have helped much, if at all. We haven’t seen the data for the first 210 because at that time the trial was still ongoing but their push to add PCR to the end point as a primary speaks volumes. Add all of the data from Buci’s ugly step sister NAC along with the in vitro studies for Buci show that it should work and work very well. Hindsight is always 20/20 but we would have certainly had the chance to change endpoints and go for an EUA if they would have tracked the symptoms data properly. If we have strong PCR data, symptoms reduction and as a secondary kept folks out of the hospital there will be value here, a lot more than our current market cap which I know isn’t saying much but value none the less!! GLTA
This is not true. As Rick, pointed out the recent endpoint that was submitted was with healthy patients, so it was unlikely that there would be statistical significance that was jaw dropping. However, prior endpoint with pcr data was very good from the first 210 that MF used it as an endpoint even though the FDA did not like the endpoint choice. Clearly, MF saw something he liked from the PCR test to try to push it through. Now, when he looks at symptom data,it will show some kind of time reduction to recover and based on other triggers, ie. glutathione recovery and 16 X NAC in strength, this is sure to have something big.
ps. I hope.
Good afternoon Hattrick. Good to hear from you again. This is all great but your thesis is based on one big "if". IF there is positive data. So far the FDA and the DSMB are not impressed so what makes you believe the 500 is going to reflect something a potential partner would see as valuable enough to get anybody's money back? I agree with what you're saying but so far we have nothing to indicate this trial has produced anything positive. In fact what we have at this point is the opposite.
The new COVID variant has symptoms that are similar to allergies. Here’s how to tell the difference
Is it pink eye, allergies… or COVID?
By TROY FARAH
Staff Writer
PUBLISHED MAY 16, 2023 12:00PM (EDT)
Red eyed man holding tissue to his nose (Getty Images/heidijpix)
Nothing in life is certain except death, taxes and that the SARS-CoV-2 virus will keep mutating. Despite both the White House and the World Health Organization recently declaring an end to the public health emergencies characterizing the last three years of the pandemic, the pathogen responsible for COVID continues to circulate, still daily infecting large numbers of people, sometimes hospitalizing and killing them or giving them long-lasting symptoms.
In the U.S., 1,100 people died from COVID the week ending May 3, so even though recent stats suggest COVID deaths dropped in 2022. Still, the disease ranks fourth among the leading causes of death in the U.S., meaning it is still killing a very high number of Americans.
It's true that infections and death are trending downward and we have better tools than ever to control COVID. But it is also true that viruses naturally mutate, often evolving new strategies to evade our defenses.
Meanwhile, as SARS-CoV-2 mutates, its symptoms often manifest differently. And the latest batch of variants that are spreading in North America appear to have symptoms very similar to allergies, especially conjunctivitis or pink eye. That means many people have COVID, thinking it's just related to the weird, exceptionally bad allergy season. Unfortunately, unlike allergies or the flu, there is nothing "mild" about COVID, not even the most recent variants, whose infections can still cause brain damage and long COVID.
The Centers for Disease Control and Prevention (CDC) keep a weekly tally estimating the total percentage of virus strains currently circulating. All of them right now are the children or grandchildren of the omicron variant that emerged in late 2021. For most of this year, Americans have been battling against Kraken (XBB.1.5), but it is slowly being superseded by its offspring, such as Arcturus (XBB.1.16).
According to CDC data, Kraken made up roughly 67 percent of cases in the week ending May 6, a decline from its peak of 84 percent in April. Meanwhile, Arcturus has jumped to around 12.5 percent of cases, a rise from just 1 percent at the end of March.
While the string of numbers and letters in a variants name may seem confusing — which is why the nicknames exist — they can represent significant differences between virus strains that manifest as entirely different symptoms. They may also allow the virus to better infect different areas of the body. The delta strain, for example, was more likely to infect the lower respiratory tract, while omicron primarily affects the upper respiratory tract, generally causing less damage to the lungs.
It's simple to clear up any confusion about whether it's COVID or allergies: Take a test. Even though the virus is constantly mutating, even the take-home COVID tests will still work typically. That's because they are designed to capture a wide variety of mutations to the N protein, which differs from the spike protein, the part of the virus used to enter our cells.
Arcturus first appeared in India, but as it makes its way through North America, it seems to be presenting feverish symptoms more commonly as well as mimicking allergies, specifically conjunctivitis. Often called pink eye, this is a reddish-pink inflammation or infection of the transparent membrane (conjunctiva) that lines your eyelid and covers the white part of your eyeball. It can be quite itchy and caused by bacteria, allergens or viruses. COVID-related conjunctivitis is seemingly more common in children, but so far, much of this data is anecdotal.
In late April, the American Academy of Ophthalmology issued a report that eye symptoms alone are probably not a sign of COVID infection. But if your kid has been exposed to the virus or have other symptoms, such as a fever, body aches, cough, or the prototypical loss of taste or smell, it's recommended to have them tested.
The vaccines still do a decent job of preventing serious illness and death from these emerging strains of COVID, but their ability to protect against infection is waning. Federal health agencies recently approved a second bivalent booster shot for immunocompromised people or those over age 65.
Does restoration of glutathione matter?
insert-text-here
Does Bucillamine restore glutathione?
Thank you
enjoy the day;0)))
No
Bard is a LLM and doesn't have access to inside information
Hattrick3
Nice and concise. Now we wait.
Ditto.
GLTUA!
3bb
Im assuming nobody. No point in selling at these losses. Holding for something positive to make her run
So how many of you sold shares? I've decided to keep all of mine, holding on to hope.
Repost..................
Another day, another semi-meltdown from some holders, and,of course, the usual slew of idiotic screeching from the court of jesters that invade the board at the first sign of any supposed ""-ve"" news re revive.
Newsflash........based on what was revealed as the pandemic progressed, and quite some time after the trial commenced, the primary eps of deaths and hospitalizations were, in hindsight, doomed to fail from day one.
Those who paid little to no attention to the liars on tv and the medical establishment who kept insisting that covid was DEADLY TO EVERYONE would have realized that this was not only false but was provably so based on the death and hospitalization data.
Who was dying and/or being hospitalized you ask?........it was almost exclusively elderly (75+) people with comorbids, and younger persons with MULTIPLE comorbids.......the data is still there and never lied!!!
Now go look at the criteria of the buccy trial on clinicaltrials and see what type of patients were sought (by invitation) to fill the slots and based on those findings one, unless theyre a complete dolt, will undoubtedly come to the same or a similar conclusion.
It seems that if the trial had been an open one with minimal medical screening that buccy may have stood a much better chance but that time has now passed.
The likelihood that such a small and refined sample, ie 700 participants, would achieve statsig for Death/Hosp was from the onset extremely low due to the entry/exclusion criteria being purposely designed to recruit HEALTY PERSONS.
Now we await the analysis of the data based on the other markers that, IMO, may show greater promise and as such could be the next catalyst for moving forward.
As ive stated before, those who got carried away and chose not to recoup their investment over the years since have no one to blame but themselves and should take this as a huge lesson,........as for the mindless gloaters, im not sure why since those like me who came into this playing the long game are still proper.
Now back to enjoying my drink...........cheers!
Note: Saw a comment that was beyond dull but I honestly expected no less........somehow its mikes fault the primary eps failed. What an absolute eejit. lololsss
Yep that’s the facts. Everything else is hope and prayers. I do hope and pray there’s enough nuggets in the rest of the data to save this pump from going to 0
Eco
Kudos for some semblance of reality here. Let see what all the data shows.
Eco
Kudos for some semblance of reality here. Let see what all the data shows.
To be clear..... (PR excerpt):
....the DSMB recommended that the Study be halted early due to statistical significance of the primary endpoint likely NOT going to be met,....
Good evening sir. I see reading comprehension, is either still lacking in most of flipper world or is it that selective quote parroting by the molesters of stocks and stock news like the recent $RVVTF great news, to the reading comprehension challenged trading shorted stocks these days is the primary issue?
Like you, I see news that I predicted that is great news.
https://www.stocktitan.net/news/RVVTF/revive-therapeutics-provides-update-of-phase-3-clinical-study-for-3x0it6c60rx7.html
Thanks. That makes sense. Back to the FDA for approval and then a sales force to push this stuff. We need help in more ways than one.
GLTA
When a company meets with the DSMB on a blinded trial the only folks that see the actual data is the DSMB. Revive did not see any of the 500 all they get is an over arching recommendation on where to go next. Officially unblinding the data will put all the raw data in Revive’s hands for the first time and stop the trial completely. This will allow them to package up whatever positive data they have in order to grab that partner or sell it outright. If they find positive symptoms reduction along with no hospitalizations or death; basically data that shows Bucillamine has promise it will put all investors in a position to make their money back. Don’t forget trials aren’t cheap! Revive’s current market cap is less than what they spent on the trial itself, crazy! Good luck!
Better to hold for 10 years than sell at these prices. Heck we're almost halfway there already :)
about the only good thing I see here is that with the data being unblinded (and I agree that they had looked at the 210 and 500ish) maybe a 'partner' that they may be talking to can now discuss with the FDA an agreement on a fresh study / endpoints and hopefully that partner has the expertise to run a fairly quick trial under new endpoints, Basically they waited too long the trial fizzled with no push towards enrollment.
I agree with you - no sense pulling the trigger here - I'll just hold tight and see what the next 3 - 5 years bring.
I hear you Gator. I still would have liked the PR to end that the trial is ending due to statistical significance. (w/o the likely being met). I'll be around waiting to see if we can get anything like a Tamiflu drug or possibly a partnership for a long covid study, but I'm not holding my breath anymore. If this stuff works for symptoms, like we think it will, we will likely get our money back. No point in selling for peanuts now.
ps. I still don't understand what is being unblinded. Didn't they unblind the 210 and recently look at 510? What is left? Maybe they are now looking specifically at symptoms for the 720 and the FDA will let it slide for a cold remedy. Other uses are there as well.
pps. We now have a 6 and dealer is showing an ace. Ugh.
ppps. Why not wait some more? Nothing more to lose now.
Today's news is good. When the trial began, no one could have anticipated how Covid would change. The primary endpoints that were set in 2020 aren't applicable. But @Revive_RVV has data now. Showing impact on symptoms is likely given everything we know about NAC. $RVV $RVVTF
— Revive Therapeutics (unofficial) (@revivethera) May 12, 2023
Patronizing little peasant aren't you? You misinterpreted my original post of course. Jog on, sad act.
I think it is clear I am not a Michael Frank fan but you are being a dick today with your posts content. We are all hurting and furious so have a bit of class eh.
The fat lady has sung. RVVTF now joins the graveyard along with RLFTF and many other biotechs attempting to profit off of COVID. IMO RVV has always been about shrooms anyhow. By his own actions, the CEO has made that clear from day one. I'm sorry for everyone's losses. I took some losses too, but fortunately I exited about the time RLFTF sunk, so I only took a small hit. I predict that within 1-12 months we'll see an R/S (just like what happened to RLFTF). RVVTF is an unprofitable company, and they will need cash to keep afloat. Unfortunately, small foreign biotechs (in this case Swiss and Canadian) have never been on the FDA radar screen IMO. GLTA.
Looks like legal speak for those who invested in the offering
Unfortunately the outlook is poor here
Anyone see this new disclaimer added in this PR?
“There can be no assurance that the Company will proceed with the clinical development and regulatory approvals of Bucillamine for COVID-19 in the U.S. and internationally.”
They would already be up over 10%
Anyone with any sense and a little powder would be taking a step back, calm down, look at that gap and buy while others are bitching like a bunch of woke schoolgirls.
Data is what partners want to see. That’s where the value is.
— Revive Therapeutics (unofficial) (@revivethera) May 12, 2023
Spending your money on golf beer and hookers. Shameful
Followers
|
337
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
36642
|
Created
|
02/23/17
|
Type
|
Free
|
Moderators Classic Warrior |
Scientific Rationale of Bucillamine
Preclinical and clinical studies have demonstrated that reactive oxygen species contribute to the destruction and programmed cell death of pulmonary epithelial cells.1 N-acetyl-cysteine (NAC) has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to restore antioxidant and to reduce the activity of cellular glutathione 2,3,4,5. Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC 6. The drug is non-toxic with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via restoration of glutathione activity and other anti-inflammatory activity, to lessen the negative consequences of SARS-CoV2 infection in the lungs.
| Psilocin Pharma Corp. has developed production solutions for the active compound Psilocybin. Our process encompassed with our intellectual property cover methods of production of Psilocybin based formulations. Psilocin Pharma Corp’s range of products have been engineered to work synergistically with the body's own natural pathways of absorption while offering a contemporary approach to consumption. Psilocin Pharma also has strong relationships with specific lab partners in certain areas like Brazil, where these formulations are legally approved and plan to sell products in these jurisdictions. | |
| |
Mental Health (Depression, PTSD & Anxiety)
|
Supplements for Brain Health & Cognitive Enhancement
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |